Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the launch of the TrueLok™ Phantom and Tornado Hinges, the latest addition to the Orthopedics TrueLok circular frame portfolio. Both hinges are designed for use with TrueLok circular frame offerings, including the TrueLok EVO Ring Fixation System introduced globally last year. The TrueLok EVO System is the only circular ring construct on the market that consis.

Orthofix Introduces New Phantom and Tornado Hinges for TrueLok Ring Fixation Systems

Orthofix Medical Inc.'s merger with SeaSpine has not significantly impacted investor sentiment or market expectations. Despite reasonable Q1 financial results, the lack of forecasted revenue growth and negative sentiment make it difficult to recommend OFIX as a buy. Investors should exercise caution and monitor the company's integration of the larger asset base.

Orthofix: No Value-Creation Since SeaSpine Merger, Reiterate Hold

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Catherine Burzik has been re-appointed as the Chair of the Company's Board of Directors. Additionally, shareholders re-elected Wayne Burris who previously served on the Orthofix board from 2021-2022. Burris will serve on the Audit and Finance and Compliance and Ethics Committees. As previously announced Jon Serbousek, who served as Executive Chairman of t.

Orthofix Announces Changes to Board of Directors

Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.

Orthofix (OFIX) Advances in ALIF Procedure With New Launch

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full commercial launch of the WaveForm® A interbody for Anterior Lumbar Interbody Fusion (ALIF) procedures. The WaveForm A interbody seamlessly integrates with the company's Meridian ALIF system for treating patients in need of fusion due to degenerative disc disease. The proprietary wave-like design of the WaveForm A interbody provides a balance of streng.

Orthofix Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the presentation of multiple clinical and scientific abstracts during the International Society for the Advancement of Spine Surgery (ISASS) annual meeting in San Francisco June 1-3, 2023. “We are pleased to support a wide range of abstracts and clinical data during the annual ISASS meeting, including the first presentation of the seven-year data from the M6-C.

Orthofix Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc With Other Clinical and Scientific Abstracts at the ISASS Annual Meeting

Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alexa Huerta - Senior Director, Investor Relations Keith Valentine - President and Chief Executive Officer John Bostjancic - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Operator Thank you for standing by. My name is Brendan, and I'll be your conference operator today.

Orthofix Medical Inc. (OFIX) Q1 2023 Earnings Call Transcript

Orthofix (OFIX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.10 per share a year ago.

Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended March 31, 2023. Net sales were $175.2 million, earnings per share (“EPS”) was $(1.71), and adjusted EPS was $(0.10). “Orthofix delivered an exceptionally strong quarter with 12% year-over-year growth on a proforma basis and by minimizing any disruption associated with the business combination in January,” said Keith Valentine, President and Chief Executive Officer o.

Orthofix Reports First Quarter 2023 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2023 financial results on Tuesday, May 9, 2023 after market close. The company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the even.

Orthofix Medical Schedules First Quarter Earnings Release and Conference Call for May 9, 2023

Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips

Orthofix's (OFIX) Fitbone TAA intramedullary limb-lengthening system is implanted through a minimally invasive procedure.

Orthofix (OFIX) Progresses With Limb-Lengthening Device

Orthofix Medical Inc. (NASDAQ:OFIX ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Alexa Huerta - Senior Director, Investor Relations Keith Valentine - President and Chief Executive Officer John Bostjancic - Chief Financial Officer Jon Serbousek - Director, Executive Chairman of the Board Doug Rice - Former Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Jeffrey Cohen - Ladenburg Thalmann Dave Turkaly - JMP Securities Operator Good afternoon and welcome to Orthofix Medical's Q4 and Full-Year 2022 Earnings Call. All participants are in a listen-only mode.

Orthofix Medical, Inc. (OFIX) Q4 2022 Earnings Call Transcript

LEWISVILLE, Texas--(BUSINESS WIRE)--(NASDAQ:OFIX) The merger of Orthofix Medical Inc. ("Orthofix") and SeaSpine Holdings Corporation ("SeaSpine") became effective as of January 5, 2023. This news release includes the financial results of stand-alone Orthofix and stand-alone SeaSpine for the fourth quarter and full year ended December 31, 2022. As such, these financial results do not include any potential accounting adjustments the merger may have on future net sales or operating results.

Orthofix Medical Reports Orthofix and SeaSpine Fourth Quarter and Full-Year 2022 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will host an Analyst Teach-In Meeting in Lewisville, TX on Monday, March 13, 2023 from 2:30 - approximately 6:30 p.m. CT.

Orthofix Medical to Hold Analyst Teach-In Meeting on March 13, 2023

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that the Company will present at the upcoming Canaccord Genuity 2023 Musculoskeletal Conference in Las Vegas, NV. Management is scheduled to present on Tuesday, March 7, 2023, at 2:00 p.m. PT. Interested parties can access a live or archived webcast of the presentation on the Investors section of the Orthofix website at ir.Orthofix.com.

Orthofix Medical to Present at Canaccord Genuity 2023 Musculoskeletal Conference

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its fourth quarter 2022 financial results of stand-alone Orthofix as well as stand-alone SeaSpine, which was merged into Orthofix effective January 5, 2023, on Monday, March 6, 2023 after market close. The company will host a conference call and webcast to review results at 4:30 p.m. ET the same day.

Orthofix Medical Schedules Fourth Quarter Earnings Release and Conference Call for March 6, 2023

LEWISVILLE, Texas--( BUSINESS WIRE )--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full commercial launch of, and first patient cases involving, the Mariner ® Deformity Pedicle Screw System.

Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System

LEWISVILLE, Texas--( BUSINESS WIRE )--(NASDAQ:OFIX) The merger of equals between Orthofix Medical Inc. ("Orthofix") and SeaSpine Holdings Corporation ("SeaSpine") became effective as of January 5, 2023. This news release includes the pre-merger unaudited preliminary net sales results of stand-alone SeaSpine and stand-alone Orthofix for the fourth quarter and full year ended December 31, 2022. As such, these preliminary financial results do not include any potential accounting adjustments that the merger may have on future net sales results.

Orthofix Medical Inc. Announces Preliminary SeaSpine and Orthofix 2022 Fourth Quarter and Full-Year Net Sales Results

LEWISVILLE, Texas--( BUSINESS WIRE )--Orthofix Medical Inc. (NASDAQ: OFIX) and SeaSpine Holdings Corporation today announced the successful completion of their previously announced merger of equals following the approval of each company's stockholders at respective special meetings of stockholders held today. Of votes cast, 99% of SeaSpine common shares were voted in approval of the merger, and 98% of Orthofix common shares were voted in approval of the merger.

Orthofix and SeaSpine Announce Completion of Merger of Equals to Create a Leading Global Spine and Orthopedics Company

LEWISVILLE, TEXAS--( BUSINESS WIRE )--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced results from a prospective, multicenter clinical study evaluating the safety and efficacy of the Trinity Elite™ cellular bone allograft (CBA) in lumbar spinal fusion procedures. Published in Neurology International , patients treated with the Trinity Elite CBA demonstrated fusion rates of 98.6 percent, measured by bridging bone at 12 months follow-up.

Orthofix Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures

SeaSpine Holdings

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of SeaSpine Holdings Corporation (NasdaqGS: SPNE) with Orthofix Medical Inc. (NasdaqGS: OFIX). Under the terms of the proposed transaction, shareholders of SeaSpine will receive only 0.4163 shares of Orthofix for each share of SeaSpine that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

SEASPINE HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of SeaSpine Holdings Corporation - SPNE

LEWISVILLE, Texas & CARLSBAD, Calif.--( BUSINESS WIRE )--Orthofix (NASDAQ: OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger.

Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

NEW YORK , Nov. 17, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Orthofix Medical Inc. (NASDAQ: OFIX). If you are a shareholder of Orthofix Medical Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/orthofix-medical-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Orthofix Medical Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming Stifel 2022 Healthcare investor conference on Wednesday, November 16, 2022 at 8:00 a.m.

News for Orthofix International Stock (OFIX)